A rare case of free bowel perforation associated with infliximab treatment for stricturing Crohn's disease.
Crohn's disease is characterized by chronic transmural inflammation of the bowel and is associated with serious complications, such as bowel strictures, abscesses, fistula formation, and perforation. As neither medical nor surgical therapy provides a cure for Crohn's disease, the primary goals of therapy are to induce and maintain remission and prevent complications. As a biologic agent, infliximab, a monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease that does not respond to other medical therapies or surgery. Infliximab has proven to be very effective for inducing and maintaining remission in Crohn's disease; however, infliximab treatment has several potential complications. Here, we report a case of free perforation following a therapeutic response after an initial dose of infliximab for Crohn's disease. This is the first case report describing a free perforation in a Crohn's disease patient after an initial dose of infliximab.
Departments of Internal Medicine, Pathology, and Surgery, Institute for Medical Science, Kosin University College of Medicine, Busan, Korea.
Chang Sup
CS
Lim
Won
W
Moon
Seun Ja
SJ
Park
Moo In
MI
Park
Hyung Hun
HH
Kim
Jong Bin
JB
Kim
Jeong Moon
JM
Choi
Hee Kyung
HK
Chang
Seung Hyun
SH
Lee
D000293:Adolescent; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D003113:Colonoscopy; D003424:Crohn Disease / Q000188:drug therapy*; D004043:Dietary Fiber; D005260:Female; D005355:Fibrosis / Q000473:pathology; D006801:Humans; D007082:Ileum / Q000601:surgery; D000069285:Infliximab; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000601:surgery; D014057:Tomography, X-Ray Computed
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D004043:Dietary Fiber; D000069285:Infliximab